Matt Sause

Chief Executive Officer, Roche Diagnostics · Roche Group

Pharmaceuticals and Diagnostics

Matt Sause leads Roche Diagnostics after commercial and country-management assignments across Asia, Europe and the Americas. His experience also includes pharmaceutical leadership at Genentech, Gilead Sciences and Roche’s Peru and Korea businesses.

Last reviewed: Nov 10, 2026

Matt Sause

Chief Executive Officer, Roche Diagnostics
Roche Group

Last Reviewed: November 10, 2026

Executive Summary

Matt Sause leads Roche Diagnostics after commercial and country-management assignments across Asia, Europe and the Americas. His experience also includes pharmaceutical leadership at Genentech, Gilead Sciences and Roche’s Peru and Korea businesses.

Career Highlights

  • Became CEO of Roche Diagnostics on January 1, 2023.

  • Has held country leadership roles in Ireland, Peru and Korea.

  • Returned from Gilead Sciences in 2019 to lead Roche Diagnostics North America.

Professional Journey

Sause joined Roche in the United States in 2002 as a Senior Molecular Account Manager. His subsequent diagnostics work included account- and product-management positions through 2008. He then moved to Tokyo as commercial operations manager for Japan and Asia-Pacific. From 2010 to 2012, he worked in Taipei as director of Applied Science and director of Molecular Diagnostics.

His first subsequent country-management assignment was in Ireland, where he led Roche Diagnostics from 2012 to 2014. He then moved into Pharmaceuticals, becoming president and general manager in Peru from 2014 to 2016 and holding the corresponding role in Korea from 2016 to 2018.

At Genentech in the United States, Sause became a vice president and lifecycle leader for Tecentriq in lung and head and neck cancers in 2018. In 2019, he joined Gilead Sciences as senior vice president and head of Global Commercial Product Strategy, before returning to Roche later that year.

On his return, he became president and chief executive of Roche Diagnostics North America, based in Indianapolis. He held that role through 2022. Roche announced his appointment as the Diagnostics Division’s next CEO in October 2022, with the appointment effective January 1, 2023.

The move also brought him onto Roche’s Corporate Executive Committee. Outside Roche, he has served on AdvaMed’s board since 2019.

Education

Sause earned a BA in microbiology at Miami University in Oxford, Ohio, in 1999 and an MBA at the University of California, San Diego, in 2006.